X

Trial Profile

Open Label Phase 2 Clinical Study of Peginterferon Lambda and Lonafarnib Boosted With Ritonavir 48-Week Combination Therapy for Delta Hepatitis

Status: Withdrawn prior to enrolment

Phase of Trial: Phase II

Latest Information Update: 27 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lonafarnib (Primary) ; Peginterferon lambda-1a (Primary) ; Ritonavir
Indications Hepatitis D
Focus Therapeutic Use
Acronyms LIFT-2

Most Recent Events

22 May 2024 Status changed from not yet recruiting to withdrawn prior to enrolment.
20 May 2024 Planned initiation date changed to 26 May 2024.
25 Apr 2024 Planned initiation date changed from 30 Apr 2024 to 1 May 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com